The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.
 
Glenn Heller
No Relationships to Disclose
 
Robert Thomas Mccormack
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Thian Kheoh
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Gilead Sciences; Janssen Oncology
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst)
 
Robert Dreicer
Honoraria - Astellas Pharma
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Exelixis; Ferring; Janssen Oncology; Medivation; Roche
Research Funding - Asana Biosciences (Inst); Genentech (Inst)
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Ronald De Wit
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Sanofi (Inst)
 
Dana T. Aftab
Employment - Exelixis
Leadership - Exelixis
Stock and Other Ownership Interests - Exelixis
Patents, Royalties, Other Intellectual Property - Cabozantinib (Inst)
 
Mohammad Hirmand
Employment - Medivation; Pfizer
Leadership - Medivation; Pfizer
Stock and Other Ownership Interests - Medivation; Pfizer
 
David B. MacLean
Employment - Takeda
 
Karim Fizazi
Honoraria - Amgen; Astellas Pharma; Janssen; Merck; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Clovis Oncology; Elsevier; Ferring; Janssen Research & Development; Med IQ; Medivation; Merck; Roche; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst); Medivation (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ferring; Medivation; Roche; WIRB-Copernicus Group